Comparison of Bioactive Glass Ceramics Spacer and PEEK Cages in Posterior Lumbar Interbody Fusion: A Prospective, RCT

Seoul National University Hospital54 enrolled

Overview

The authors aimed to compare the clinical efficacy and safety of CaO-SiO2-P2O5-B2O3 glass ceramics with PEEK cage that is widely used for posterior lumbar interbody fusion (PLIF) surgery in the clinical field.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Degenerative Lumbar Spinal Stenosis

Interventions

NovoMax, BioAlpha Inc, Seong-nam, KoreaDEVICE

CaO-SiO2-P2O5-B2O3 glass ceramics spacer

PEEK cageDEVICE

PEEK cage

Eligibility

Sex: ALLMin age: 30 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients aged between 30 and 80 * patients who required one-level PLIF between L1 and S1 among those who required an extensive laminectomy or facetectomy to correct severe disc extrusion or severe spinal stenosis or those who required PLIF due to grade I or II spondylolisthesis * those who (only if a signature was obtainable), or whose legal guardian, fully understood the clinical trial details and signed the informed consent form. Exclusion Criteria: * osteoporosis patients with average T-scores of L1-L4 at \<-3.0 in DEXA bone density tests * women with positive pregnancy tests before the trial or who planned to become pregnant within the following 3 years * patients with a history of malignant tumor or malignant diseases (but the cases of cured disease with no relapse for the past 5 years were included in the present study) * patients with abnormal blood potassium and phosphorus levels; * patients with liver disease, kidney disease, respiratory disease, metabolic disease, or psychological disease; * patients deemed to have less than 1-year life expectancy; * patients with mental retardation or whose parents or legal guardians were older or had mental disabilities; * other patients viewed as inappropriate by the staff

Locations (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyounggido, South Korea

Outcomes

Primary Outcomes

Fusion rates

This is assessed by postoperative computed tomography at 1 year after surgery

Time frame: up to 5 year after operation

Secondary Outcomes

Visual Analog Pain Scale (VAS)

VAS is a measurement score that indicates pain severity status. VAS score comprised a 10-cm line with ''none'' (0) on one end of the scale and ''disabling pain'' (10) on the other.

Time frame: 3, 6, and 12, months, and every year, up to 5 year after operation

Oswestry Disability Index (ODI)

The ODI is based on a self-administered questionnaire measuring ''back-specific function.'' The questionnaire comprises 10 items, each with 6 levels of response. Each item is scored from 0 to 5, and the total summation is converted to a 0-100 scale.20 The ODI scores ranges from 0 to 100, with higher scores indicating severe symptoms.

Time frame: 3, 6, and 12, months, and every year, up to 5 year after operation

EQ-5D

EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. This can be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scores on these five dimensions can be presented as a health profile or can be converted to a single summary index number (utility) reflecting preferability compared to other health profiles.

Time frame: 3, 6, and 12, months, and every year, up to 5 year after operation

PainDETECT

The painDETECT Questionnaire (PDQ) is a screening tool designed to detect neuropathic pain in patients with chronic low back pain (LBP) based on self-reported pain characteristics. The degree of the seven types of pain quality, the type of pain pattern, and the presence of radiating pain. From the three components of the PDQ, a total score is calculated; a high score indicates that the pain is likely to have a neuropathic component. Scoring is performed using a scoring manual, and results in a final screening score: a score of 0-12 indicates nociceptive pain, 19-38 indicates neuropathic pain, and 13-18 indicates mixed pain.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.